Pharmaceutical

GSK remains resilient on tariffs as Q1 sales rise 4%

GSK said it remains confident it can absorb the financial impact of potential US tariffs as it posted a 4% rise in Q1 2025 sales.

May 2, 2025 - 06:00
GSK remains resilient on tariffs as Q1 sales rise 4%
GSK said it remains confident it can absorb the financial impact of potential US tariffs as it posted a 4% rise in Q1 2025 sales.
Read the original article

Tags:

Previous Article

End-to-end solutions: why every link in the pharmaceutical supply chain counts

Next Article

Novartis to strengthen renal disease portfolio with Regulus

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

CD123-targeted CAR-NK by Chongqing Precision Biotech fo...

Oct 3, 2023

FDA approves Sandoz’s Enzeevu as Eylea biosimilar saga continues

FDA approves Sandoz’s Enzeevu as Eylea biosimilar saga ...

Aug 13, 2024

STAT+: After sickle-cell screwups, Bluebird Bio’s only option might be a company sale

STAT+: After sickle-cell screwups, Bluebird Bio’s only ...

Dec 11, 2023